Imaxe de Portada

Immunotherapy in Myeloma

Immunotherapy in multiple myeloma, first investigated with allogeneic stem cell transplantation, is now a major pillar in the treatment of multiple myeloma. CAR-T-cell technology, monoclonal or bispecific antibodies, as well as new forms of cellular therapy, have revolutionized the treatment of this...

Descrición completa

Gardado en:
Formato: Online
Idioma:inglés
Publicado: MDPI - Multidisciplinary Digital Publishing Institute 2022
Subjects:
multiple myeloma
immunotherapy
daratumumab
BCMA
bi-specific T cell engagers
chimeric antigen receptor
relapse
cytokine-release syndrome
allogeneic transplantation
myeloablative
non-myeloablative
new drugs
CAR T
antibodies
monoclonal
bispecific
immunoconjugates
antibody-drug conjugates
myeloma
NK cells
immunomodulation
cell therapy
graft-versus-myeloma
donor lymphocyte infusion
allogeneic stem cell transplantation
prophylaxis
salvage
CAR T-cells
target antigen
n/a
thema EDItEUR::M Medicine and Nursing
Acceso en liña:ONIX_20220224_9783036529073_75
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
Summary:Immunotherapy in multiple myeloma, first investigated with allogeneic stem cell transplantation, is now a major pillar in the treatment of multiple myeloma. CAR-T-cell technology, monoclonal or bispecific antibodies, as well as new forms of cellular therapy, have revolutionized the treatment of this hematological malignancy.

Títulos similares